A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605479054 | ||
| 003 | CHVBK | ||
| 005 | 20210128100408.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150901xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10741-015-9496-5 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10741-015-9496-5 | ||
| 245 | 0 | 2 | |a A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms |h [Elektronische Daten] |c [Farzin Beygui, Manuel Anguita, Ulrich Tebbe, Josep Comin-Colet, Michel Galinier, Peter Bramlage, Eva Turgonyi, Katharina Lins, Lynda Imekraz, Trinidad de Frutos, Michael Böhm] |
| 520 | 3 | |a Heart failure (HF) is commonly described according to the severity of symptoms, using the New York Heart Association (NYHA) classification, and the assessment of ventricular function, by measuring the left ventricular ejection fraction (LVEF). It is important to acknowledge, however, that the severity of symptoms does not systematically correlate with the level of ventricular systolic dysfunction. Patients with no or only mild symptoms are still at high risk of HF-related morbidity and mortality. The objective of this review was to summarize the prevalence, characteristics, and treatment of patients with chronic HF and mild or no symptoms and to review epidemiological data from three recent registries conducted in Europe. From a clinical practice perspective, patients with a reduced ejection fraction who have only mild symptoms appear to represent a group of patients for whom the provision of adequate medical care is yet to be optimized. While prescription of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers appears to be consistently high, the use of mineralocorticoid receptor antagonists is more variable and does not appear to be in accordance with the latest clinical guidelines. As approximately half of patients with HF and a reduced LVEF have NYHA class II symptoms, significant reductions in morbidity and mortality could be achieved by more comprehensive treatment of this population. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Heart failure |2 nationallicence | |
| 690 | 7 | |a NYHA II |2 nationallicence | |
| 690 | 7 | |a Pharmacotherapy |2 nationallicence | |
| 690 | 7 | |a Ejection fraction |2 nationallicence | |
| 700 | 1 | |a Beygui |D Farzin |u Department of Cardiology, University Hospital of Caen Basse-Normandie, Caen, France |4 aut | |
| 700 | 1 | |a Anguita |D Manuel |u Cardiology, Heart Failure and Transplant Program, Hospital University Reina Sofia, Cordoba, Spain |4 aut | |
| 700 | 1 | |a Tebbe |D Ulrich |u Abteilung für Kardiologie, Angiologie und Intensivmedizin, Klinikum Lippe-Detmold, Detmold, Germany |4 aut | |
| 700 | 1 | |a Comin-Colet |D Josep |u Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain |4 aut | |
| 700 | 1 | |a Galinier |D Michel |u Department of Cardiology A, University Hospital of Toulouse - Rangueil Hospital, Toulouse, France |4 aut | |
| 700 | 1 | |a Bramlage |D Peter |u Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831, Mahlow, Germany |4 aut | |
| 700 | 1 | |a Turgonyi |D Eva |u Pfizer Ltd., Dorking Rd, KT20 7NS, Tadworth, UK |4 aut | |
| 700 | 1 | |a Lins |D Katharina |u Pfizer Ltd., Dorking Rd, KT20 7NS, Tadworth, UK |4 aut | |
| 700 | 1 | |a Imekraz |D Lynda |u Pfizer France, Paris, France |4 aut | |
| 700 | 1 | |a de Frutos |D Trinidad |u Pfizer Spain SLU, Madrid, Spain |4 aut | |
| 700 | 1 | |a Böhm |D Michael |u Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany |4 aut | |
| 773 | 0 | |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/5(2015-09-01), 545-552 |x 1382-4147 |q 20:5<545 |1 2015 |2 20 |o 10741 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10741-015-9496-5 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10741-015-9496-5 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Beygui |D Farzin |u Department of Cardiology, University Hospital of Caen Basse-Normandie, Caen, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Anguita |D Manuel |u Cardiology, Heart Failure and Transplant Program, Hospital University Reina Sofia, Cordoba, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tebbe |D Ulrich |u Abteilung für Kardiologie, Angiologie und Intensivmedizin, Klinikum Lippe-Detmold, Detmold, Germany |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Comin-Colet |D Josep |u Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Galinier |D Michel |u Department of Cardiology A, University Hospital of Toulouse - Rangueil Hospital, Toulouse, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Bramlage |D Peter |u Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831, Mahlow, Germany |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Turgonyi |D Eva |u Pfizer Ltd., Dorking Rd, KT20 7NS, Tadworth, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lins |D Katharina |u Pfizer Ltd., Dorking Rd, KT20 7NS, Tadworth, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Imekraz |D Lynda |u Pfizer France, Paris, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a de Frutos |D Trinidad |u Pfizer Spain SLU, Madrid, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Böhm |D Michael |u Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/5(2015-09-01), 545-552 |x 1382-4147 |q 20:5<545 |1 2015 |2 20 |o 10741 | ||